NASDAQ:SLXP

Salix Pharmaceuticals (SLXP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
4.96 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SLXP stock logo

About Salix Pharmaceuticals Stock (NASDAQ:SLXP)

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

SLXP Stock News Headlines

Pharmaceuticals News
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
His win rate puts Warren Buffett to shame…
Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.
DNDNQ News
Canada's Valeant to buy Salix in $10.1 billion deal
See More Headlines
Receive SLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SLXP
CUSIP
79543510
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

SLXP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Salix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salix Pharmaceuticals investors own include Allergan (AGN), Baidu (BIDU), Gilead Sciences (GILD), (QIHU) (QIHU), Capri (CPRI), 3D Systems (DDD), Intercept Pharmaceuticals (ICPT), Johnson & Johnson (JNJ) and

This page (NASDAQ:SLXP) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners